Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study

Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
This study was retracted.
Study covers HCQ and favipiravir.
Dabbous et al., 25 Jan 2021, peer-reviewed, 10 authors.
This PaperFavipiravirAll
RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Hany M Dabbous, Sherief Abd-Elsalam, Manal H El-Sayed, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Samir Abd El Ghafar, Shaimaa Soliman, Mohamed Elbahnasawy, Rehab Badawi, Mohamed Awad Tageldin
Archives of Virology, doi:10.1007/s00705-021-04956-9
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID-19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295.
Compliance with ethical standards
References
Abd-Elsalam, Elkadeem, Glal, Chloroquine as chemoprophylaxis for COVID-19: Will this work?, Infect Disord Drug Targets, doi:10.2174/1871526520666200726224802
Abd-Elsalam, Esmail, Khalaf, Tanta protocol for management of COVID-19. Perspectives from a developing country, Endocr Metab Immune Disord Drug Targets, doi:10.2174/1871530320999201117142305
Abena, Chloroquine and hydroxychloroquine for the prevention or treatment of COVID-19 in Africa: caution for inappropriate off-label use in healthcare settings, Am J Trop Med Hyg
Arab-Zozani, Hassanipour, Ghoddoosi-Nejad, Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials, BMJ Open
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, doi:10.1016/j.eng.2020.03.007
Cascella, Rajnik, Cuomo, Features, evaluation and treatment coronavirus (COVID-19
Doi, Ikeda, Hayase, Nafamostat mesylate treatment incombination with favipiravir for patients critically ill with Covid-19: a case series, Crit Care
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther
Faul, Erdfelder, Lang, A flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav Res Methods
Furuta, Mechanism of action of T-705 against influenza virus, Antimicrob Agents Chemother
Goldhill, Velthuis, Fletcher, The mechanism of resistance to favipiravir in influenza, Proc Natl Acad Sci
Hernandez, Roman, Pasupuleti, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med
Inoue, Jinno, Ohta, Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD, Respir Med Case Rep
Irie, Nakagawa, Fujita, Pharmacokinetics of favipiravir in critically Ill patients with COVID-19, Clin Transl Sci
Madelain, Oestereich, Graw, Ebola virus dynamics in mice treated with favipiravir, Antiviral Res
Marjot, Moon, Cook, Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study, J Hepatol, doi:10.1016/j.jhep.2020.09.024
Mohamed, Mohamed, Mohamoud, SARS-CoV-2: the path of prevention and control, Infect Disord Drug Targets, doi:10.2174/1871526520666200520112848
Noda, Shirai, Nakajima, Case report: two cases of COVID-19 pneumonia including use of favipiravir
Oestereich, Lüdtke, Wurr, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res
Sarin, Choudhury, Lau, Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study), Hepatol Int, doi:10.1007/s12072-020-10072-8
Xie, Chen, Insight into 2019 novel coronavirus-an updated intrim review and lessons from SARS-CoV and MERS-CoV, Int J Infect Dis, doi:10.1016/j.ijid.2020.03.071
Yazdany, Kim, Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know, Ann Intern Med
Yin, Wunderink, MERS, SARS and other coronaviruses as causes of pneumonia, Respirology
Yokoyama, Oguri, Kato, Case report a case of COVID-19 pneumonia that did not worsen and was relieved by early administration of favipiravir and ciclesonide
Zhu, Chen, Gorshkov, Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective, SLAS DIS-COV Adv Sci Drug Discov, doi:10.1080/07391102.2020.1761882
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T16:01:05Z', 'timestamp': 1715616065990}, 'update-to': [ { 'updated': { 'date-parts': [[2021, 11, 22]], 'date-time': '2021-11-22T00:00:00Z', 'timestamp': 1637539200000}, 'DOI': '10.1007/s00705-021-04956-9', 'type': 'retraction', 'label': 'Retraction'}], 'reference-count': 28, 'publisher': 'Springer Science and Business Media LLC', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2021, 1, 25]], 'date-time': '2021-01-25T00:00:00Z', 'timestamp': 1611532800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2021, 1, 25]], 'date-time': '2021-01-25T00:00:00Z', 'timestamp': 1611532800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 3]]}, 'DOI': '10.1007/s00705-021-04956-9', 'type': 'journal-article', 'created': {'date-parts': [[2021, 1, 25]], 'date-time': '2021-01-25T10:06:58Z', 'timestamp': 1611569218000}, 'page': '949-954', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 108, 'title': 'RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized ' 'study', 'prefix': '10.1007', 'volume': '166', 'author': [ {'given': 'Hany M.', 'family': 'Dabbous', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4366-2218', 'authenticated-orcid': False, 'given': 'Sherief', 'family': 'Abd-Elsalam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manal H.', 'family': 'El-Sayed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmed F.', 'family': 'Sherief', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fatma F. S.', 'family': 'Ebeid', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Mohamed Samir Abd', 'family': 'El Ghafar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shaimaa', 'family': 'Soliman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed', 'family': 'Elbahnasawy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rehab', 'family': 'Badawi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed Awad', 'family': 'Tageldin', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 1, 25]]}, 'reference': [ { 'issue': '8', 'key': '4956_CR1', 'doi-asserted-by': 'publisher', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'volume': '382', 'author': 'N Zhu', 'year': '2020', 'unstructured': 'Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A novel ' 'coronavirus from patients with pneumonia in China, 2019. N Engl J Med. ' '382(8):727–733', 'journal-title': 'N Engl J Med.'}, { 'issue': '2', 'key': '4956_CR2', 'doi-asserted-by': 'publisher', 'first-page': '130', 'DOI': '10.1111/resp.13196', 'volume': '23', 'author': 'Y Yin', 'year': '2018', 'unstructured': 'Yin Y, Wunderink RG (2018) MERS, SARS and other coronaviruses as causes ' 'of pneumonia. Respirology 23(2):130–137', 'journal-title': 'Respirology'}, { 'key': '4956_CR3', 'volume-title': 'Features, evaluation and treatment coronavirus (COVID-19)', 'author': 'M Cascella', 'year': '2012', 'unstructured': 'Cascella M, Rajnik M, Cuomo A et al (2012) Features, evaluation and ' 'treatment coronavirus (COVID-19). StatPearls Publishing, Treasure ' 'Island'}, { 'key': '4956_CR4', 'doi-asserted-by': 'publisher', 'first-page': '754', 'DOI': '10.7326/M20-1334', 'volume': '172', 'author': 'J Yazdany', 'year': '2020', 'unstructured': 'Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and chloroquine ' 'during the COVID-19 pandemic: what every clinician should know. Ann ' 'Intern Med. 172:754–755', 'journal-title': 'Ann Intern Med.'}, { 'issue': '4', 'key': '4956_CR5', 'doi-asserted-by': 'publisher', 'first-page': '287', 'DOI': '10.7326/M20-2496', 'volume': '173', 'author': 'AV Hernandez', 'year': '2020', 'unstructured': 'Hernandez AV, Roman YM, Pasupuleti V et al (2020) Hydroxychloroquine or ' 'chloroquine for treatment or prophylaxis of COVID-19: a living ' 'systematic review. Ann Intern Med. 173(4):287–296', 'journal-title': 'Ann Intern Med.'}, { 'issue': '2', 'key': '4956_CR6', 'doi-asserted-by': 'publisher', 'first-page': '242', 'DOI': '10.1002/cpt.1844', 'volume': '108', 'author': 'YX Du', 'year': '2020', 'unstructured': 'Du YX, Chen XP (2020) Favipiravir: pharmacokinetics and concerns about ' 'clinical trials for 2019-nCoV infection. Clin Pharmacol Ther ' '108(2):242–247', 'journal-title': 'Clin Pharmacol Ther'}, { 'issue': '7', 'key': '4956_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e039730', 'DOI': '10.1136/bmjopen-2020-039730', 'volume': '10', 'author': 'M Arab-Zozani', 'year': '2020', 'unstructured': 'Arab-Zozani M, Hassanipour S, Ghoddoosi-Nejad D (2020) Favipiravir for ' 'treating patients with novel coronavirus (COVID-19): protocol for a ' 'systematic review and meta-analysis of randomised clinical trials. BMJ ' 'Open. 10(7):e039730', 'journal-title': 'BMJ Open.'}, { 'issue': '45', 'key': '4956_CR8', 'doi-asserted-by': 'publisher', 'first-page': '11613', 'DOI': '10.1073/pnas.1811345115', 'volume': '115', 'author': 'DH Goldhill', 'year': '2018', 'unstructured': 'Goldhill DH, Te Velthuis AJ, Fletcher RA et al (2018) The mechanism of ' 'resistance to favipiravir in influenza. Proc Natl Acad Sci ' '115(45):11613–11618', 'journal-title': 'Proc Natl Acad Sci'}, { 'key': '4956_CR9', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/2472555220942123', 'author': 'W Zhu', 'year': '2020', 'unstructured': 'Zhu W, Chen CZ, Gorshkov K et al (2020) RNA-dependent RNA polymerase as ' 'a target for COVID-19 Drug discovery. SLAS DISCOV Adv Sci Drug Discov. ' 'https://doi.org/10.1177/2472555220942123', 'journal-title': 'SLAS DISCOV Adv Sci Drug Discov'}, { 'key': '4956_CR10', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/07391102.2020.1761882', 'author': 'AA Elfiky', 'year': '2020', 'unstructured': 'Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) ' 'targeting: an in silico perspective. J Biomol Struct Dyn. ' 'https://doi.org/10.1080/07391102.2020.1761882', 'journal-title': 'J Biomol Struct Dyn'}, { 'key': '4956_CR11', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1871526520666200520112848', 'author': 'AA Mohamed', 'year': '2020', 'unstructured': 'Mohamed AA, Mohamed N, Mohamoud S et al (2020) SARS-CoV-2: the path of ' 'prevention and control. Infect Disord Drug Targets. ' 'https://doi.org/10.2174/1871526520666200520112848 (Online ahead of ' 'print)', 'journal-title': 'Infect Disord Drug Targets'}, { 'issue': '5', 'key': '4956_CR12', 'doi-asserted-by': 'publisher', 'first-page': '690', 'DOI': '10.1007/s12072-020-10072-8', 'volume': '14', 'author': 'SK Sarin', 'year': '2020', 'unstructured': 'Sarin SK, Choudhury A, Lau GK et al (2020) Pre-existing liver disease is ' 'associated with poor outcome in patients with SARS CoV2 infection; the ' 'APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int ' '14(5):690–700. https://doi.org/10.1007/s12072-020-10072-8', 'journal-title': 'Hepatol Int'}, { 'key': '4956_CR13', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1871526520666200726224802', 'author': 'S Abd-Elsalam', 'year': '2020', 'unstructured': 'Abd-Elsalam S, Elkadeem M, Glal KA (2020) Chloroquine as ' 'chemoprophylaxis for COVID-19: Will this work? Infect Disord Drug ' 'Targets. https://doi.org/10.2174/1871526520666200726224802 (Online ahead ' 'of print)', 'journal-title': 'Infect Disord Drug Targets.'}, { 'key': '4956_CR14', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1871530320999201117142305', 'author': 'S Abd-Elsalam', 'year': '2020', 'unstructured': 'Abd-Elsalam S, Esmail ES, Khalaf M et al (2020) Tanta protocol for ' 'management of COVID-19. Perspectives from a developing country. Endocr ' 'Metab Immune Disord Drug Targets. ' 'https://doi.org/10.2174/1871530320999201117142305 (Online ahead of ' 'print)', 'journal-title': 'Endocr Metab Immune Disord Drug Targets'}, { 'key': '4956_CR15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.03.071', 'author': 'M Xie', 'year': '2020', 'unstructured': 'Xie M, Chen Q (2020) Insight into 2019 novel coronavirus—an updated ' 'intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. ' 'https://doi.org/10.1016/j.ijid.2020.03.071 ([Epub ahead of print])', 'journal-title': 'Int J Infect Dis'}, { 'key': '4956_CR16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jhep.2020.09.024', 'author': 'T Marjot', 'year': '2020', 'unstructured': 'Marjot T, Moon AM, Cook JA et al (2020) Outcomes following SARS-CoV-2 ' 'infection in patients with chronic liver disease: an international ' 'registry study. J Hepatol. https://doi.org/10.1016/j.jhep.2020.09.024 ' '(Online ahead of print. PMID: 33035628)', 'journal-title': 'J Hepatol'}, { 'key': '4956_CR17', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eng.2020.03.007', 'author': 'Q Cai', 'year': '2020', 'unstructured': 'Cai Q, Yang M, Liu D et al (2020) Experimental treatment with ' 'favipiravir for COVID-19: an open-label control study. Engineering ' '(Beijing). https://doi.org/10.1016/j.eng.2020.03.007 ([Epub ahead of ' 'print])', 'journal-title': 'Engineering (Beijing)'}, { 'key': '4956_CR18', 'doi-asserted-by': 'publisher', 'first-page': '175', 'DOI': '10.3758/BF03193146', 'volume': '39', 'author': 'F Faul', 'year': '2007', 'unstructured': 'Faul F, Erdfelder E, Lang A-G et al (2007) A flexible statistical power ' 'analysis program for the social, behavioral, and biomedical sciences. ' 'Behav Res Methods 39:175–191', 'journal-title': 'Behav Res Methods'}, { 'key': '4956_CR19', 'unstructured': 'World Health Organization. Coronavirus disease (COVID-19) situation ' 'report—139. ' 'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2. ' 'Accessed 8 June 2020.'}, { 'key': '4956_CR20', 'doi-asserted-by': 'publisher', 'first-page': '17', 'DOI': '10.1016/j.antiviral.2014.02.014', 'volume': '105', 'author': 'L Oestereich', 'year': '2014', 'unstructured': 'Oestereich L, Lüdtke A, Wurr S et al (2014) Successful treatment of ' 'advanced Ebola virus infection with T-705 (favipiravir) in a small ' 'animal model. Antiviral Res 105:17–21', 'journal-title': 'Antiviral Res'}, { 'key': '4956_CR21', 'doi-asserted-by': 'publisher', 'first-page': '70', 'DOI': '10.1016/j.antiviral.2015.08.015', 'volume': '123', 'author': 'V Madelain', 'year': '2015', 'unstructured': 'Madelain V, Oestereich L, Graw F et al (2015) Ebola virus dynamics in ' 'mice treated with favipiravir. Antiviral Res 123:70–77', 'journal-title': 'Antiviral Res'}, { 'key': '4956_CR22', 'unstructured': 'Noda A, Shirai T, Nakajima H et al (2020) Case report: two cases of ' 'COVID-19 pneumonia including use of favipiravir. The Japanese ' 'Association for Infectious Diseases. ' 'http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200408_2.pdf'}, { 'key': '4956_CR23', 'unstructured': 'Yokoyama K, Oguri T, Kato A et al (2020) Case report a case of COVID-19 ' 'pneumonia that did not worsen and was relieved by early administration ' 'of favipiravir and ciclesonide. ' 'http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200406.pdf.'}, { 'key': '4956_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1184', 'DOI': '10.4269/ajtmh.20-0290', 'volume': '102', 'author': 'PM Abena', 'year': '2020', 'unstructured': 'Abena PM et al (2020) Chloroquine and hydroxychloroquine for the ' 'prevention or treatment of COVID-19 in Africa: caution for inappropriate ' 'off-label use in healthcare settings. Am J Trop Med Hyg 102:1184–1188', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '4956_CR25', 'doi-asserted-by': 'publisher', 'first-page': '981', 'DOI': '10.1128/AAC.49.3.981-986.2005', 'volume': '49', 'author': 'Y Furuta', 'year': '2005', 'unstructured': 'Furuta Y et al (2005) Mechanism of action of T-705 against influenza ' 'virus. Antimicrob Agents Chemother. 49:981–986', 'journal-title': 'Antimicrob Agents Chemother.'}, { 'issue': '5', 'key': '4956_CR26', 'doi-asserted-by': 'crossref', 'first-page': '880', 'DOI': '10.1111/cts.12827', 'volume': '13', 'author': 'K Irie', 'year': '2020', 'unstructured': 'Irie K, Nakagawa A, Fujita H et al (2020) Pharmacokinetics of ' 'favipiravir in critically Ill patients with COVID-19. Clin Transl Sci. ' '13(5):880–885', 'journal-title': 'Clin Transl Sci.'}, { 'key': '4956_CR27', 'doi-asserted-by': 'publisher', 'first-page': '392', 'DOI': '10.1186/s13054-020-03078-z', 'volume': '24', 'author': 'K Doi', 'year': '2020', 'unstructured': 'Doi K, Ikeda M, Hayase N et al (2020) Nafamostat mesylate treatment ' 'incombination with favipiravir for patients critically ill with ' 'Covid-19: a case series. Crit Care 24:392', 'journal-title': 'Crit Care'}, { 'key': '4956_CR28', 'first-page': '101200', 'volume': '31', 'author': 'H Inoue', 'year': '2020', 'unstructured': 'Inoue H, Jinno M, Ohta S et al (2020) Combination treatment of ' 'short-course systemic corticosteroid and favipiravir in a successfully ' 'treated case of critically ill COVID-19 pneumonia with COPD. Respir Med ' 'Case Rep 31:101200', 'journal-title': 'Respir Med Case Rep'}], 'container-title': 'Archives of Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s00705-021-04956-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s00705-021-04956-9/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s00705-021-04956-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 10, 19]], 'date-time': '2023-10-19T01:58:46Z', 'timestamp': 1697680726000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s00705-021-04956-9'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1, 25]]}, 'references-count': 28, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2021, 3]]}}, 'alternative-id': ['4956'], 'URL': 'http://dx.doi.org/10.1007/s00705-021-04956-9', 'relation': {}, 'ISSN': ['0304-8608', '1432-8798'], 'subject': [], 'container-title-short': 'Arch Virol', 'published': {'date-parts': [[2021, 1, 25]]}, 'assertion': [ { 'value': '14 October 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '25 November 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '25 January 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '3 August 2021', 'order': 4, 'name': 'change_date', 'label': 'Change Date', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Clarification', 'order': 5, 'name': 'change_type', 'label': 'Change Type', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': "Editor's Note:The Editor-in-Chief is currently investigating this article as " 'concerns have been raised about the reporting of this clinical trial. Further ' 'editorial action will be taken as appropriate once the investigation into the ' 'concerns is complete and all parties have been given an opportunity to respond ' 'in full.', 'order': 6, 'name': 'change_details', 'label': 'Change Details', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '22 November 2021', 'order': 7, 'name': 'change_date', 'label': 'Change Date', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Correction', 'order': 8, 'name': 'change_type', 'label': 'Change Type', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'This article has been retracted. Please see the Retraction Notice for more ' 'detail:', 'order': 9, 'name': 'change_details', 'label': 'Change Details', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'https://doi.org/10.1007/s00705-021-05307-4', 'URL': 'https://doi.org/10.1007/s00705-021-05307-4', 'order': 10, 'name': 'change_details', 'label': 'Change Details', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance with ethical standards'}}, { 'value': 'There are no conflicts of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit